Objective: To analyze the frequency of thrombocytosis diagnosed in general health examination institutions and the background of examinees to consider the direction of secondary screening.
Methods: We analyzed the complete blood count data collected at health examination foundation-related facilities from fiscal year 2016 to fiscal year 2020. Furthermore, we conducted detailed analysis including past medical history and current medical history for examinees in fiscal year 2020.
Results: The total number of platelet tests conducted and the number of cases meeting the criteria of the Japan Society of Ningen Dock and Preventive Medical Care Grade D (platelet count of 400,000/μL or higher) and the diagnostic criteria for essential thrombocythemia (ET) of the World Health Organization (platelet count of 450,000/μL or higher) at four health examination foundation-affiliated facilities from 2016 to 2020 were as follows:
· Fiscal year 2016: 43,964/805 (1.8%)/264 (0.60%)
· Fiscal year 2017: 50,171/1,095 (2.18%)/346 (0.69%)
· Fiscal year 2018: 54,854/1,222 (2.23%)/426 (0.78%)
· Fiscal year 2019: 59,160/1,464 (2.47%)/493 (0.83%)
· Fiscal year 2020: 62,420/1,678 (2.69%)/548 (0.88%)
Among the cohort of examinees undergoing total platelet tests, the number of individuals subjected to ET examination was 0.6–0.9% annually (approximately 500 individuals). The incidence of thrombocytosis was 1.5 to 2 times higher in females than in males, with a tendency towards microcytic anemia observed.
Conclusion: It was found that approximately 1% of all health examination attendees may be candidates for secondary examination for thrombocytosis. Currently, we are developing a comprehensive data analysis program that can comprehensively understand factors such as sustained hematopoietic increases and referral and attendance status for the same examinee.
View full abstract